Canaccord Genuity initiated Furiex Pharmaceuticals FURX with a Buy rating and a $45.00 price target.
Canaccord Genuity noted, "We like these type of stories that include a combination of: (1) highly visible cash-based valuation upside potential; (2) sizable pipeline opportunities that we think are under-appreciated; (3) catalysts that can unlock value; and (4) a limited following that has the story off the radar of many. Our launch timing coincides with the Friday evening US approval of DPP-4 inhibitor Nesina (along with two combo drugs) by partner Takeda that we think can bring an inflection in the stock. Our $45 target implies 112% upside."
Furiex Pharmaceuticals closed at $21.24 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in